Oxalys Pharmaceuticals

Oxalys Pharmaceuticals is located in Toronto, Canada on 112 College St #411. Oxalys Pharmaceuticals is rated 3 out of 5 in the category pharmaceutical company in Canada. Oxalys is developing disease-modifying therapeutics for neurodegenerative disorders, including Huntington’s, Parkinson’s, and Alzheimer’s diseases. The company’s therapeutic pipeline is derived from its proprietary drug discovery platform that involves high-content screening of transgenic primary neurons. The company takes a global collaborative approach to product development. The Oxalys lead therapeutic, OXD4, is being developed as a treatment of Huntington’s disease.